

Mr. CONZEN. I can't answer this question. I can find out. Probably there are such studies in these numbers.

Senator NELSON. I would appreciate it, for the record, if you would advise us, when you have the chance to check it, whether any of these were double-blind clinical tests evaluating the therapeutic comparative value of Meticorten versus any other prednisone, and if they are, the committee would appreciate it if you would send us copies of those double-blind clinical tests.

Mr. CONZEN. Yes, sir.

(The information referred to, subsequently received, follows:)

SCHERING CORP.,

Bloomfield, N.J., August 15, 1967.

HON. GAYLORD NELSON,
U.S. Senate,
Washington, D.C.

DEAR SENATOR NELSON: In the course of his appearance before your Monopoly Subcommittee on July 24, Mr. Conzen referred to the fact that there were, to date, some 1,979 published clinical papers on Meticorten, and he was interrogated by you as to how many covered clinical work in the United States, as distinguished from abroad. Mr. Conzen replied that he did not have the information with him, and that he would furnish it (Tr. pp. 1033-4).

He also was asked whether any of these included "double-blind" tests; again he offered to obtain this information for you (Ibid).

Additionally, you inquired as to our "nonprescription" sales totals in the United States; Mr. Conzen agreed to supply that figures (Tr. p. 1042).

Finally, in the course of the discussion concerning the marketing of prednisone overseas you expressed interest in ascertaining whether "competing foreign-produced prednisone" was being marketed in Switzerland; it was indicated that this information could be made available.

Responsive to the foregoing, we submit the following information:

(1) Of the total number of publications to which reference was made, namely 1,979, our review indicates that 1,416 were in the United States and 563 were outside the United States.

(2) Four publications appear to have consisted of "double-blind" studies:

a. Smyth, Charley J. A method of drug evaluation in rheumatoid arthritis: results with phenylbutazone, oxyphenylbutazone, cortisone and prednisone, *Ann. N.Y. Acad. Sc.* 86:292-306, March 30, 1960.

b. Spilka, Conrad J. The place of corticosteroids and antihistamines in oral surgery. *Oral Surg.* 14:1034-42, Sept. 1961.

c. Combined Rheumatic Fever Study Group. A comparison of short-term intensive prednisone and acetylsalicylic acid therapy in the treatment of acute rheumatic fever. *New England J. Med.* 272:63-70, Jan. 14, 1965.

d. Dordick, Jack R. and Gluck, Edward J. Preliminary clinical trials with prednisone (Meticorten) in rheumatic diseases. *J.A.M.A.* 158:166-70, May 21, 1955.

Six publications appear to have been "controlled," although not "double-blind," studies:

a. Hutchison, J. L. and Burgen, A. S. V. Infusion of non-autologous plasma. Effects of chlorpheniramine, prednisolone and adrenaline. *Brit. M.J.* 2: 904-8, Oct. 12, 1963.

b. Bollet, Alfred J., et al. Treatment of systemic lupus erythematosus with prednisone and prednisolone. *J.A.M.A.* 159:1501-7, Dec. 15, 1955.

c. Bunim, Joseph J., et al. Studies on metacortandralone and metacortandracin in rheumatoid arthritis. *J.A.M.A.* 157: 311-18, Jan. 22, 1955.

d. Calkins, Evan, et al. Comparison of the metabolic effects of prednisone and cortisone. *Ann Rheumat. Dis.* 14: 419, Dec., 1955.

e. Bosch, Samuel J., et al. Prolonged use of prednisone in rheumatoid arthritis and disseminated lupus erythematosus. *Medicina panam.* 11: 258-62, Sept. 15, 1958.

f. Sicuteri, F. and Ficini, M. Effects of prednisone on the symptomatology and histamine cranialgic sensitivity in medical cephalaea. *Minerva med.* 46: 1744-48, Dec. 12, 1955.

As Mr. Conzen stated in his testimony, we are not aware of any "double-blind" studies comparing Meticorten with other brands of prednisone. However, the